Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibody > Rituximab > RIB-Y37

Anti-Rituximab Antibody (AY37) (recommended for PK/PD)

Order Now

  • Source
    Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')2.
  • Isotype
    Mouse IgG1/kappa
  • Specificity
    Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
Rituximab SDS-PAGE

Anti-Rituximab Antibody (AY37) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa
 Rituximab ELISA

Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) at 2 μg/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibody (Cat. No. RIB-BY35) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL.

 Rituximab ELISA

Demonstration of the specificity of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) to the rituximab.

Bioactivity-FACS
 Rituximab FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 μg/ml (Routinely tested).

  • Background
    Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $300.00

Price(USD) : $2180.00

Promotion & Exhibitions



Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message